A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control and adding savory flavors are ways that ...

Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

The NHS had been facing supply issues with glucagon-like peptide receptor agonists (GLP-1 RAs, or GLP-1 analogues), a range of drugs used for managing blood glucose levels in people with type 2 ...

Evidence for this mechanism lies in the fact that the protein composition ... of glucagon secretion. In addition to glucagon, a novel proglucagon-derived peptide, proglucagon 1-61 (PG 1-61) comprised ...

Department of Chemical Engineering, University of Illinois Chicago, Chicago, Illinois 60607, United States Department of Chemical Engineering, University of Illinois Chicago, Chicago, Illinois 60607, ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Of those, over 215,000 had been prescribed a glucagon-like peptide-1 (GLP-1) agonist receptor — the class of drugs that includes Ozempic, Wegovy, Mounjaro, Zepbound, and others — and 1.7 ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1.

The following is a summary of “Metabolic Effects of Glucagon Stimulations in Type 1 Diabetes and Healthy Controls,” published in the January 2025 issue of Endocrinology by She et al. Researchers ...